Drug Trial Radar · NCT07910903
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
May 2030
Study completion Nov 2030
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM). Part 2 is to compare the efficacy of CM336 + CM313 (Group A) with Daratumumab + Pomalidomide +Dexamethasone (DPd) (Group B) in RRMM patients.
Conditions
- Multiple Myeloma (MM)
Interventions
CM336Drug
Specified dose on specified days
CM313Drug
Specified dose on specified days
DaratumumabDrug
Specified dose on specified days
PomalidomideDrug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Frequency of Adverse Events (AEs)Time frame: Up to 4 years
- Part 2: 9-Month Minimal Residual Disease (MRD) Negative Complete Response (CR)Time frame: At month 9
- Part 2: Progression Free Survival (PFS)Time frame: Up to 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.